Panagora Asset Management Inc Mei Pharma, Inc. Transaction History

Panagora Asset Management Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.42 - $0.65 $34,818 - $53,886	-82,902 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.54 - $2.74 $13,041 - $66,171	-24,150 Reduced 22.56%	82,902 $50,000
Q4 2021 Feb 10, 2022	SELL	$2.33 - $3.37 $414,262 - $599,169	-177,795 Reduced 62.42%	107,052 $286,000
Q3 2021 Nov 10, 2021	SELL	$2.52 - $2.99 $58,806 - $69,774	-23,336 Reduced 7.57%	284,847 $786,000
Q2 2021 Aug 11, 2021	BUY	$2.6 - $3.65 $287,817 - $404,051	110,699 Added 56.05%	308,183 $878,000

Q1 2021 May 12, 2021	SELL	$2.73 - $4.5 $883,567 - $1.46 Million	-323,651 Reduced 62.11%	197,484 $677,000
Q4 2020 Feb 10, 2021	SELL	$2.6 - $3.32 $29,686 - $37,907	-11,418 Reduced 2.14%	521,135 $1.38 Million
Q3 2020 Nov 13, 2020	BUY	$2.46 - $4.27 $95,937 - $166,525	38,999 Added 7.9%	532,553 $1.66 Million
Q2 2020 Aug 12, 2020	BUY	$1.45 - $4.3 $502,823 - $1.49 Million	346,775 Added 236.26%	493,554 $2.04 Million
Q1 2020 May 14, 2020	BUY	$0.75 - $2.55 $12,428 - $42,256	16,571 Added 12.73%	146,779 $236,000
Q4 2019 Feb 12, 2020	BUY	$1.65 - $2.48 $214,843 - $322,915	130,208 New	130,208 $323,000
Q4 2018 Feb 14, 2019	SELL	$1.92 - $4.1 $32,006 - $68,347	-16,670 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$3.39 - $4.61 $2,705 - $3,678	-798 Reduced 4.57%	16,670 $72,000
Q2 2018 Aug 14, 2018	SELL	$1.89 - $4.95 $52,763 - $138,189	-27,917 Reduced 61.51%	17,468 $69,000
Q4 2017 Feb 14, 2018	SELL	$1.91 - $2.83 $2,255 - $3,342	-1,181 Reduced 2.54%	45,385 $95,000
Q3 2017 Nov 14, 2017	BUY	$2.44 - $2.91 $113,621 - $135,507	46,566	46,566 $125,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $373M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.